Toll Free: 1-888-928-9744

Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 489 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016', provides an overview of the Refractory Acute Myeloid Leukemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia
- The report reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Refractory Acute Myeloid Leukemia therapeutics and enlists all their major and minor projects
- The report assesses Refractory Acute Myeloid Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 6 Refractory Acute Myeloid Leukemia Overview 7 Therapeutics Development 8 Refractory Acute Myeloid Leukemia - Therapeutics under Development by Companies 10 Refractory Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 14 Refractory Acute Myeloid Leukemia - Pipeline Products Glance 15 Refractory Acute Myeloid Leukemia - Products under Development by Companies 18 Refractory Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 23 Refractory Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 24 Refractory Acute Myeloid Leukemia - Therapeutics Assessment 80 Drug Profiles 97 Refractory Acute Myeloid Leukemia - Recent Pipeline Updates 285 Refractory Acute Myeloid Leukemia - Dormant Projects 466 Refractory Acute Myeloid Leukemia - Discontinued Products 468 Refractory Acute Myeloid Leukemia - Product Development Milestones 469 Appendix 478
List of Tables
Number of Products under Development for Refractory Acute Myeloid Leukemia, H1 2016 18 Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Number of Products under Development by Companies, H1 2016 (Contd..1) 21 Number of Products under Development by Companies, H1 2016 (Contd..2) 22 Number of Products under Development by Companies, H1 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Comparative Analysis by Late Stage Development, H1 2016 25 Comparative Analysis by Clinical Stage Development, H1 2016 26 Comparative Analysis by Early Stage Development, H1 2016 27 Products under Development by Companies, H1 2016 28 Products under Development by Companies, H1 2016 (Contd..1) 29 Products under Development by Companies, H1 2016 (Contd..2) 30 Products under Development by Companies, H1 2016 (Contd..3) 31 Products under Development by Companies, H1 2016 (Contd..4) 32 Products under Investigation by Universities/Institutes, H1 2016 33 Refractory Acute Myeloid Leukemia - Pipeline by 4SC AG, H1 2016 34 Refractory Acute Myeloid Leukemia - Pipeline by AbbVie Inc., H1 2016 35 Refractory Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 36 Refractory Acute Myeloid Leukemia - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016 37 Refractory Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2016 38 Refractory Acute Myeloid Leukemia - Pipeline by Amgen Inc., H1 2016 39 Refractory Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 40 Refractory Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H1 2016 41 Refractory Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H1 2016 42 Refractory Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 43 Refractory Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 44 Refractory Acute Myeloid Leukemia - Pipeline by BioLineRx, Ltd., H1 2016 45 Refractory Acute Myeloid Leukemia - Pipeline by BioSight Ltd., H1 2016 46 Refractory Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H1 2016 47 Refractory Acute Myeloid Leukemia - Pipeline by Boston Biomedical, Inc., H1 2016 48 Refractory Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2016 49 Refractory Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H1 2016 50 Refractory Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H1 2016 51 Refractory Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 52 Refractory Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H1 2016 53 Refractory Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 54 Refractory Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H1 2016 55 Refractory Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H1 2016 56 Refractory Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H1 2016 57 Refractory Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 58 Refractory Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics, Inc., H1 2016 59 Refractory Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H1 2016 60 Refractory Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H1 2016 61 Refractory Acute Myeloid Leukemia - Pipeline by GlycoMimetics, Inc., H1 2016 62 Refractory Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H1 2016 63 Refractory Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H1 2016 64 Refractory Acute Myeloid Leukemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016 65 Refractory Acute Myeloid Leukemia - Pipeline by Johnson & Johnson, H1 2016 66 Refractory Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H1 2016 67 Refractory Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 68 Refractory Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 69 Refractory Acute Myeloid Leukemia - Pipeline by Les Laboratoires Servier SAS, H1 2016 70 Refractory Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H1 2016 71 Refractory Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H1 2016 72 Refractory Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 73 Refractory Acute Myeloid Leukemia - Pipeline by NantKwest, Inc., H1 2016 74 Refractory Acute Myeloid Leukemia - Pipeline by Novartis AG, H1 2016 75 Refractory Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H1 2016 76 Refractory Acute Myeloid Leukemia - Pipeline by Pfizer Inc., H1 2016 77 Refractory Acute Myeloid Leukemia - Pipeline by Pharma Mar, S.A., H1 2016 78 Refractory Acute Myeloid Leukemia - Pipeline by Plexxikon Inc., H1 2016 79 Refractory Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 80 Refractory Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H1 2016 81 Refractory Acute Myeloid Leukemia - Pipeline by Sigma-Tau S.p.A., H1 2016 82 Refractory Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016 83 Refractory Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 84 Refractory Acute Myeloid Leukemia - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 85 Refractory Acute Myeloid Leukemia - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 86 Refractory Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 87 Refractory Acute Myeloid Leukemia - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 88 Refractory Acute Myeloid Leukemia - Pipeline by Verastem, Inc., H1 2016 89 Assessment by Monotherapy Products, H1 2016 90 Assessment by Combination Products, H1 2016 91 Number of Products by Stage and Target, H1 2016 93 Number of Products by Stage and Mechanism of Action, H1 2016 99 Number of Products by Stage and Route of Administration, H1 2016 104 Number of Products by Stage and Molecule Type, H1 2016 106 Refractory Acute Myeloid Leukemia Therapeutics - Recent Pipeline Updates, H1 2016 295 Refractory Acute Myeloid Leukemia - Dormant Projects, H1 2016 477 Refractory Acute Myeloid Leukemia - Dormant Projects (Contd..1), H1 2016 478 Refractory Acute Myeloid Leukemia - Discontinued Products, H1 2016 479


List of Figures
Number of Products under Development for Refractory Acute Myeloid Leukemia, H1 2016 18 Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Comparative Analysis by Late Stage Development, H1 2016 25 Comparative Analysis by Clinical Stage Development, H1 2016 26 Comparative Analysis by Early Stage Products, H1 2016 27 Assessment by Monotherapy Products, H1 2016 90 Number of Products by Top 10 Targets, H1 2016 92 Number of Products by Stage and Top 10 Targets, H1 2016 92 Number of Products by Top 10 Mechanism of Actions, H1 2016 98 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 98 Number of Products by Routes of Administration, H1 2016 103 Number of Products by Stage and Routes of Administration, H1 2016 103 Number of Products by Molecule Types, H1 2016 105 Number of Products by Stage and Molecule Types, H1 2016 105

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify